Cargando…

RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors?

Detalles Bibliográficos
Autor principal:	Strand, Vibeke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Treatments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893664/ https://www.ncbi.nlm.nih.gov/pubmed/33597207 http://dx.doi.org/10.1136/rmdopen-2021-001565

Ejemplares similares

Waiting for JAK inhibitor safety data
por: Kragstrup, Tue Wenzel, et al.
Publicado: (2022)

Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy
por: Ghalandari, Nafise, et al.
Publicado: (2022)

JAK inhibitors disrupt T cell-induced proinflammatory macrophage activation
por: Nyirenda, Mukanthu H, et al.
Publicado: (2023)

JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications
por: Russell, Mark D, et al.
Publicado: (2023)

Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database
por: Stajszczyk, Marcin, et al.
Publicado: (2023)

Paternal mitochondria from an rmd-2, rmd-3, rmd-6 triple mutant are properly positioned in the C. elegans zygote
por: Juanico, Iris Y, et al.
Publicado: (2021)

Introducing RMD Open
por: Cutolo, Maurizio, et al.
Publicado: (2015)

Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension
por: Li, Wanjing, et al.
Publicado: (2022)

Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF
por: Cachen, Laurie, et al.
Publicado: (2022)

Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice
por: Rosano, Giuseppe, et al.
Publicado: (2020)

Treatment of hypertension with angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers and resting metabolic rate: A cross‐sectional study
por: Pedrianes‐Martin, Pablo B., et al.
Publicado: (2021)

Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010–2019
por: Setyawan, Juliana, et al.
Publicado: (2021)

Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors
por: Pitt, Bertram, et al.
Publicado: (2015)

Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology
por: Caprioli, Marta, et al.
Publicado: (2017)

Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview
por: Toussirot, Éric, et al.
Publicado: (2016)

Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study
por: Christensen, Ingrid Egeland, et al.
Publicado: (2022)

Effectiveness of angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers on total and cardiovascular mortality and morbidity in primary prevention: A nationwide study based on French Health Insurance Data (SNDS)
por: Oger, Emmanuel, et al.
Publicado: (2022)

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration
por: Lauper, Kim, et al.
Publicado: (2022)

DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors
por: Dicker, Dror
Publicado: (2011)

JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
por: Degryse, Sandrine, et al.
Publicado: (2015)

The use of SGLT2 inhibitors in achieving glycaemic control in maturity-onset diabetes of the young type 3
por: Sriravindrarajah, Arunan, et al.
Publicado: (2021)

RMD: a rice mutant database for functional analysis of the rice genome
por: Zhang, Jianwei, et al.
Publicado: (2006)

Incidence and factors associated with prescribing renin‐angiotensin‐system inhibitors in adult idiopathic nephrotic syndrome: A nationwide cohort study
por: Nishiwaki, Hiroki, et al.
Publicado: (2021)

Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
por: Blume-Peytavi, Ulrike, et al.
Publicado: (2015)

Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin–angiotensin system inhibitors in type 2 diabetic patients with albuminuria
por: Cooper, Mark E., et al.
Publicado: (2019)

Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study
por: Choi, Se Rim, et al.
Publicado: (2023)

Efficacy and safety of IL inhibitors, TNF-α inhibitors, and JAK inhibitors in patients with ankylosing spondylitis: a systematic review and Bayesian network meta-analysis
por: Tian, Cong, et al.
Publicado: (2023)

RMD86, a thiophene derivative, promotes antinociceptive and antipyretic activities in mice
por: da Cruz, Ryldene Marques Duarte, et al.
Publicado: (2020)

Factors affecting drug survival of an alternative TNF inhibitor and secukinumab in patients with ankylosing spondylitis switching from the first TNF inhibitor
por: Kwon, Oh Chan, et al.
Publicado: (2021)

The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia
por: Gordon, Max J., et al.
Publicado: (2021)

The CivaSheet: The new frontier of intraoperative radiation therapy or a pricier alternative to LDR brachytherapy?
por: Seneviratne, Danushka, et al.
Publicado: (2017)

Commentary: Tackling the Challenges of Developing Targeted Therapies for Cancer
por: Schilsky, Richard L., et al.
Publicado: (2010)

Important adverse events to be evaluated in antidepressant trials and meta-analyses in depression: a large international preference study including patients and healthcare professionals
por: Chevance, Astrid, et al.
Publicado: (2022)

Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?
por: Kotyla, Przemysław J., et al.
Publicado: (2021)

A double‐blind, placebo‐controlled trial on the antihypertensive treatment effect of a quadruple single‐pill combination
por: Hu, Lei‐Xiao, et al.
Publicado: (2021)

Assessing costs of a hypertension management program: An application of the HEARTS costing tool in a program planning workshop in Thailand
por: Husain, Muhammad Jami, et al.
Publicado: (2019)

Pulmonary Embolism and Heart Failure: A Reappraisal
por: Arrigo, Mattia, et al.
Publicado: (2021)

The safety of JAK-1 inhibitors
por: Clarke, Benjamin, et al.
Publicado: (2021)

JAK1 Selective inhibitors
por: Edwards, Christopher
Publicado: (2021)

Twelve-Month Follow-up Results from a Randomized Controlled Trial of a Brief Personalized Feedback Intervention for Problem Drinkers
por: Cunningham, John A., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_q9e0lvtrmsdnmq20adq4nqph2g